The compounds compared on this page are research-grade reference peptides supplied strictly for in-vitro and other controlled laboratory research. They are not for human or animal consumption, are not FDA approved for any use represented here, and are not drugs, supplements, cosmetics, or treatments for any condition. This article is third-person science education describing how published preclinical work distinguishes three related synthetic secretagogues.
It does not describe or endorse taking, dosing, or administering any substance, and every question about human safety or suitability belongs with a licensed clinician.
What the GHRP Family Is
GHRP stands for growth hormone releasing peptide. The label covers a group of short synthetic peptides developed from work on enkephalin derivatives that share a common property: each one triggers growth hormone release from pituitary tissue through a receptor distinct from the receptor used by growth hormone releasing hormone itself. That receptor was characterized before its natural ligand was, which is part of why the family kept the functional name it was given at discovery.
The receptor is now designated the growth hormone secretagogue receptor, GHS-R1a, and its endogenous ligand is ghrelin. Every compound discussed here is a synthetic agonist at that receptor. This matters for interpreting the comparison below, because the differences between these three molecules are not differences of target. They all bind the same receptor. They differ in how strongly they engage it, what else they engage alongside it, and how the receptor population behaves over the course of an experiment. Background on how short peptide sequences act as signaling molecules is covered in the primer on what peptides are, and the broader family context sits in the growth hormone peptides category.
- Shared target: the growth hormone secretagogue receptor GHS-R1a, whose endogenous ligand is ghrelin.
- GHRP-6: a hexapeptide, the first-generation reference compound in the family.
- GHRP-2: a hexapeptide developed after GHRP-6, studied for higher secretagogue potency with a smaller appetite-signaling component.
- Hexarelin: a hexapeptide, the most potent of the three in the catalog, with reported activity beyond the pituitary.
- Research status: all three are reference materials for controlled laboratory study only, never medicines, supplements, or cosmetics.
- Catalog listings and specifications: GHRP-2, GHRP-6, and Hexarelin.
Why These Three Are Compared
These three compounds are compared constantly in research discussion because they occupy the same functional slot and cannot be treated as interchangeable. A laboratory setting up a growth hormone pulse study has to choose one, and the choice changes what the resulting data can support. Choosing on the basis of potency alone is the most common error, because the most potent compound in a family is rarely the cleanest, and cleanliness is usually what determines whether a result can be attributed to a single variable.
The comparison also matters because these molecules behave differently over time within the same experiment. Receptor systems adapt. A compound that produces a large response on first exposure may produce a diminishing response under continued exposure, and that adaptation is itself a documented property of this receptor family rather than an artifact of poor material. A study design that does not account for it will produce a time course that looks like compound failure when it is actually receptor desensitization.
Finally, the three differ in what they do outside the growth hormone axis. Signaling at GHS-R1a is not confined to somatotroph cells, and published work reports effects on appetite circuitry, on prolactin and cortisol, and in the case of one compound on cardiac tissue. Those additional effects are confounds in a study about growth hormone and are the primary endpoint in a study about something else. The right compound depends entirely on which of those two studies is being run.
GHRP-6: The First-Generation Reference Compound
GHRP-6 is a hexapeptide and the original member of the family in wide research use. Its defining characteristic in the literature is not its growth hormone response, which is substantial, but the size of the appetite signaling response that accompanies it. Because GHS-R1a is the ghrelin receptor, and because ghrelin is centrally involved in hunger signaling, agonism at this receptor engages appetite circuitry as well as the somatotroph population. GHRP-6 engages it strongly.
In a study whose endpoint is growth hormone release, that appetite response is a confound. Feeding behavior changes downstream metabolic state, and downstream metabolic state changes many of the secondary measures a growth hormone study would want to record. A researcher who selects GHRP-6 for a clean growth hormone question has introduced a variable that will have to be controlled for or explained.
In a study whose endpoint is the ghrelin axis itself, the same property is the reason to select it. Appetite and metabolism research uses GHRP-6 precisely because the hunger signaling response is pronounced and therefore measurable. The compound has not changed; the question has. This is the single most useful idea for reading any comparison in this family, and it applies again to each of the compounds below.
GHRP-2: The Middle Term
GHRP-2 was developed after GHRP-6 and is studied as a more potent secretagogue with a smaller appetite signaling component. It is frequently described in research discussion as a middle position between the strong appetite response of GHRP-6 and the narrow selectivity of Ipamorelin, and that framing is reasonable as long as it is understood as a relative statement rather than an absolute one. GHRP-2 still engages the ghrelin receptor, so it still carries some of the associated signaling.
The practical consequence is that GHRP-2 tends to be chosen when a study needs a robust growth hormone response and can tolerate a modest confound, rather than when a study needs the cleanest possible isolation of a single variable. Published work in this family also reports effects on prolactin and cortisol across the non-selective secretagogues, and research designs commonly include those measures rather than assuming they are unchanged.
GHRP-2 also appears frequently in combination research alongside a growth hormone releasing hormone analog such as CJC-1295. The rationale is mechanistic rather than additive: the two compound classes act at different receptors on the same cell population, so their combined effect in published models is studied as a question about pathway convergence rather than as a matter of stacking two similar things. That mechanism is described in more detail in the CJC-1295 research profile.
Hexarelin: Potency and Desensitization
Hexarelin is the most potent growth hormone secretagogue of the three, and its research literature is dominated by two consequences of that potency. The first is receptor desensitization. Published work reports that continued exposure produces a declining response, which is why study designs involving hexarelin are commonly cycled rather than continuous. A researcher who runs a continuous exposure protocol and observes a falling growth hormone response over time has not necessarily observed compound degradation; the receptor population may simply have adapted.
The second consequence is the breadth of the response. Hexarelin is reported to raise prolactin and cortisol more than the more selective members of the family, which again is either noise or signal depending on the question. It is also the member of this group with the most substantial literature on activity outside the pituitary, specifically reported signaling in cardiac tissue that appears to be independent of the growth hormone pathway. That line of research treats hexarelin as a cardiovascular tool compound rather than as a secretagogue at all.
Because of the desensitization property, time course design is not a secondary detail in hexarelin work. The interval between exposures, the total duration, and whether the protocol includes washout periods will shape the result as much as concentration does. Two laboratories using identical material at identical concentrations can report different outcomes if one used a continuous design and the other a cycled one, and neither result is wrong.
Where Ipamorelin Sits Relative to the Three
Ipamorelin is not one of the three compounds in the title, but it belongs in the comparison because it defines the selective end of the range and is the reference point against which the other three are usually described. It is a pentapeptide rather than a hexapeptide, and it is reported in published work to stimulate growth hormone release with substantially less effect on prolactin and cortisol than the older secretagogues, and with a smaller appetite signaling response.
That selectivity is the reason it is often the correct choice for a study about growth hormone specifically. Isolating one variable is the entire purpose of selecting a selective agonist. The tradeoff is that a selective compound answers a narrower question, and a researcher studying the ghrelin axis broadly will find that narrowness unhelpful rather than valuable.
Arranging the four compounds along a single axis running from selective to broad is a useful mental model, with Ipamorelin at the selective end, GHRP-2 next, then GHRP-6, then Hexarelin. It is a simplification, because the compounds differ in more than one dimension and potency does not track selectivity perfectly, but it captures the main tradeoff. Further detail on the selective end of the range is in the Ipamorelin research profile.
Selecting a Compound by Research Question Rather Than by Potency
The recurring theme across every section above is that these compounds are not ranked. They are differentiated. A comparison table that scores them from best to worst is answering a question that does not exist, because the property that makes one compound the correct tool for a feeding study is the same property that disqualifies it from a clean growth hormone study.
Framing the selection as a series of questions is more productive than framing it as a ranking. The list below sets out the mapping that published research designs tend to follow, stated as research questions rather than as recommendations, since nothing here is a recommendation about acquiring or administering anything.
- Question about growth hormone release with minimal hormonal confound: the selective end of the range is the usual choice, which in this catalog means Ipamorelin rather than any of the three compared here.
- Question about the ghrelin and appetite axis: GHRP-6, because the pronounced hunger signaling response is the measurable endpoint rather than an interference.
- Question requiring a robust secretagogue response with a moderate confound tolerance: GHRP-2, which is why it is described as the middle term.
- Question about maximal secretagogue stimulation or about receptor desensitization kinetics: Hexarelin, with a cycled rather than continuous design.
- Question about cardiac tissue signaling independent of the growth hormone pathway: Hexarelin, which has the most substantial literature in that area among the three.
- Question about convergence between the secretagogue receptor and the growth hormone releasing hormone receptor: a secretagogue paired with a GHRH analog, a design described further in the growth hormone secretagogues guide.
Handling, Storage, and Why Purity Decides the Result
All three compounds are supplied as lyophilized powder, the standard format for research peptides because removing water substantially extends the shelf life of the solid material. Stability differs sharply between the dry and the reconstituted state. Sealed lyophilized powder held cold and dry is comparatively stable; solution stability depends on solvent, concentration, temperature, and how often the container is opened. Repeated freeze and thaw cycles degrade peptide integrity without producing any visible change in the vial, which is why aliquoting reconstituted stock into single-use volumes is standard practice.
Concentration arithmetic deserves deliberate attention in this family in particular, because the three compounds are supplied in different vial sizes and are frequently compared side by side in the same experiment. Carrying a calculation across from a previous vial of a different mass is an easy way to be wrong by a large factor. A calculator is available at the reconstitution calculator, and the underlying chemistry is covered in peptide chemistry and solubility.
Purity is a precondition for interpreting any of the distinctions described on this page rather than a documentation formality. The entire comparison above rests on the claim that one compound produces more appetite signaling than another, or more prolactin response, or faster desensitization. If a preparation contains synthesis-related byproducts, truncated sequences, or uncharacterized counterion content, an observed difference between two vials may reflect the contaminant profile rather than the molecules named on the labels. These three sequences are also closely related hexapeptides, which raises the specific risk that an identity error is not obvious from the way a preparation behaves.
- Lyophilized powder: store sealed, cold, and dry, protected from moisture ingress.
- Reconstituted stock: aliquot into single-use volumes rather than repeatedly thawing a single container.
- Verify vial mass before every calculation rather than reusing arithmetic from a prior experiment.
- Confirm identity by mass spectrometry and purity by high performance liquid chromatography for the specific lot, not for a representative batch.
- Certificate scope and testing methodology are described at Certificate of Analysis and in purity testing and COA.
What This Page Is and Is Not
This page is a description of how published preclinical literature distinguishes three synthetic secretagogues that share a receptor. It is written for researchers evaluating which reference compound answers a given question in a controlled laboratory setting, and every statement about compound behavior describes findings reported in cell culture and animal models rather than outcomes in people.
None of the material discussed here is a drug, a supplement, a cosmetic, or a treatment for any condition, and none of it is for human or animal consumption. No dosing information appears on this page, and no part of it should be read as guidance about acquiring, administering, or self-experimenting with any substance. Questions about safety, suitability, or health belong with a licensed clinician rather than with a research supplier.
Related material is available across the site: answer-first topics are collected at questions, longer-form science guides at learn, and specifications and availability for approved research accounts are handled through order.
Create a free research account to view current pricing and bundles and place an order.
Frequently asked questions
What does GHRP stand for?
GHRP stands for growth hormone releasing peptide. The term covers a group of short synthetic peptides that stimulate growth hormone release from pituitary tissue through the growth hormone secretagogue receptor GHS-R1a, whose endogenous ligand is ghrelin. The name was assigned from the functional effect observed at discovery, before the receptor and its natural ligand were characterized. All compounds in the family are research-use-only reference materials, not drugs or supplements.
Do GHRP-2, GHRP-6, and Hexarelin act on different receptors?
No. All three are synthetic agonists at the same target, the growth hormone secretagogue receptor GHS-R1a. The differences reported between them in preclinical research are differences of potency, of selectivity, of what additional signaling accompanies receptor engagement, and of how the receptor population adapts to continued exposure. They are not differences of target, which is why the three cannot be ranked simply and are instead selected according to the research question.
Why is GHRP-6 associated with appetite signaling in research?
Because GHS-R1a is the ghrelin receptor, and ghrelin is centrally involved in hunger signaling, agonism at that receptor engages appetite circuitry alongside the somatotroph population. GHRP-6 engages it strongly in published animal work. That response is a confound in a study whose endpoint is growth hormone release and is the measurable endpoint in a study of the ghrelin and appetite axis. The property is the same in both cases; only the research question differs.
What is receptor desensitization and why does it matter for Hexarelin?
Desensitization describes a receptor population becoming less responsive under continued exposure to an agonist. Published work reports this effect with Hexarelin, which is why study designs in that literature are commonly cycled rather than continuous. It matters for interpretation because a declining response across a time course can reflect receptor adaptation rather than compound degradation, and two laboratories using identical material can report different outcomes if one used a continuous design and the other a cycled one.
Which of these three is the most selective?
Among the three compared here, GHRP-2 is described in research discussion as having the smallest appetite signaling component, with GHRP-6 larger and Hexarelin broadest in its accompanying effects. None of the three is the selective end of the wider family. That position belongs to Ipamorelin, a pentapeptide reported in published work to stimulate growth hormone release with substantially less effect on prolactin and cortisol than the older secretagogues.
Is the most potent compound the best choice for research?
Not generally. Potency describes how strongly a compound engages its receptor, not how cleanly it isolates a variable, and in this family the most potent member carries the broadest accompanying signaling and the most pronounced desensitization. A study seeking to attribute an effect to a single pathway usually needs selectivity rather than maximal response. Compound selection follows the research question rather than a potency ranking.
Why are these compounds supplied as lyophilized powder?
Removing water through lyophilization substantially extends the shelf life of the solid material, because water participates in the chemical reactions that degrade peptide sequences over time. Sealed lyophilized powder held cold and dry is comparatively stable, while solution stability depends on solvent, concentration, temperature, and handling. Repeated freeze and thaw cycles degrade peptide integrity without any visible change in the vial, so single-use aliquots are standard laboratory practice.
Why does purity matter for a comparison like this one?
Because every distinction described on this page is a claim that one compound behaves differently from another. If a preparation contains synthesis-related byproducts, truncated sequences, or uncharacterized counterion content, an observed difference between two vials may belong to the contaminant profile rather than to the compounds on the labels. These three are closely related hexapeptides, so an identity error may not be obvious from behavior alone, which is why lot-specific mass spectrometry identity confirmation and high performance liquid chromatography purity data are read together.
All guides · Order research peptides
External references: U.S. Food and Drug Administration · Peptide (Wikipedia)